Key facts
- It has raised $54.6M across 2 recorded rounds; the latest was PIPE ($54.6M) in Feb 2021.
- 2 institutional filers report fund marks on MaxCyte across 7 filings.
- MaxCyte has filed 4 Form Ds with the SEC since 2009, most recently Sep 2016 ($760K sold to 9 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for MaxCyte
Create free account
No card required
Funding rounds
2 roundsFeb 2021PIPE$54.6M▮
About MaxCyte
- Industry
- Drug Discovery
PA Mark — not yet priced
MaxCyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in MaxCyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest Apr 20262 SEC-registered funds reported 7 fair-value marks on MaxCyte between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.